Incentive takeover moves closer as Gambro posts solid results
This article was originally published in Clinica
As Gambro revealed healthy results for 1995, the company's board recommended that shareholders accept Incentive's offer to take full control of the Swedish medtech group. Incentive acquired 49.4% of Gambro's share capital and 73.5% of its voting rights on January 2nd (see Clinica No 687, p 1). Shareholders have until the end of February to decide whether to sell their stake to Incentive at a price of SKr 155 per B share.
You may also be interested in...
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.
The International Generic and Biosimilar Medicines Association has urged the World Intellectual Property Organization to withdraw its support for a global database of pharmaceutical patent information. The Pat-INFORMED database – which is comprised of intellectual-property information provided by originators – contains unverified data and lacks appropriate safeguards, the IGBA contends.
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.